All In Biotech

Drug Trial Radar · NCT06302257

Pain Selective Anesthesia for Labor Mobility (PSALM Study): a Randomized Controlled Trial of Combined Lidocaine - Chlorprocaine for Labor Epidural Analgesia

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 303 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

303

Planned (sponsor's estimate)

Start

Mar 12, 2024

Primary completion

Mar 1, 2028

Study completion Mar 1, 2028

Sponsor

Lead sponsor
Hadassah Medical OrganizationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current "gold standard" epidural analgesia for labor is associated with unwanted side effects, such as motor block (affecting ambulation and the ability to push) and sympathetic blockade (causing maternal hypotension). Here, using direct clinical application of preclinical findings, the investigator assess a novel method for prolonged pain-selective anesthesia during labor avoiding motor block, sympathetic block or other neural side effects. The approach is based on the pain-selective anesthesia the investigator developed in preclinical models, where the exclusive presence of TRPV1 channels on pain fibers (nociceptors) was exploited. The investigator used polarized, membrane-impermeable local anesthetics, together with the co-administration of direct TRPV1 agonists to open TRPV1 channels, so allowing these impermeable local anesthetics to gain selective access to nociceptors. Early preclinical studies used capsaicin as the TRPV1 agonist and QX-314 as the polarized local anesthetic, but neither of these drugs are appropriate for clinical use. Here the investigators use lidocaine as the TRPV1 activator and chloroprocaine as the polarized local anesthetic and hypothesize that this co-administration will elicit pain-selective (nociceptor-specific) anesthesia for labor without side effects. Positive findings in this study will be the first evidence in humans of pain-selective local anesthesia and will be the harbinger for future studies of systemic and regional administration of these drugs for pain-selective local anesthesia for chronic and other pain states.

Conditions

  • Labor Pain

Interventions

  • ChlorprocaineDrug

    Study participants will receive chloroprocaine alone, together with standard epidural fentanyl (2mcg/mL in the epidural mixture).

  • LidocaineDrug

    Study participants will receive lidocaine alone - together with standard epidural fentanyl (2mcg/mL in the epidural mixture).

  • Lidocaine-chlorprocaine combinationDrug

    study participants randomized to this study arm will receive a a 50:50 mixture of lidocaine and chloroprocaine (based on the ED50s of each drug from Stage 1A and on the synergistic interactions from Stage 1B) - together with standard epidural fentanyl (2mcg/mL in the epidural mixture).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. VAS pain score / modified Bromage motor block scoreTime frame: At baseline and every 10 minutes for the first 30 minutes and then every 15 minutes there on after for 165 minutes (or until delivery).

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Hadassah Hebrew University Medical Center, POB 12000

    Jerusalem, Israel · Recruiting

  • Hadassah Mount Scopus

    Jerusalem, Israel · Recruiting

  • Kaplan Medical Center

    Rehovot, Israel · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.